$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000162828019010189 Filed on August 07, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q4
Revenue	$60.85M	$53.98M	$32.87M
YoY Change	180.51%	178.48%
Cost Of Revenue	$18.51M	$16.83M	$13.95M
YoY Change	84.18%	68.98%
Gross Profit	$42.33M	$37.14M	$18.93M
YoY Change	263.66%	294.27%
Gross Profit Margin	69.57%	68.81%	57.59%
Selling, General & Admin	$35.24M	$32.88M	$29.66M
YoY Change	63.21%	59.82%
% of Gross Profit	83.26%	88.52%	156.68%
Research & Development	$24.57M	$19.53M	$16.65M
YoY Change	72.38%	69.05%
% of Gross Profit	58.04%	52.59%	87.96%
Depreciation & Amortization	$2.500M	$2.200M	$6.100M
YoY Change	47.06%	69.23%	335.71%
% of Gross Profit	5.91%	5.92%	32.22%
Operating Expenses	$59.81M	$52.41M	$46.31M
YoY Change	66.86%	63.14%
Operating Profit	-$17.48M	-$15.27M	-$27.38M
YoY Change	-27.8%	-32.75%
Interest Expense	$280.0K	$287.0K	$2.240M
YoY Change	-7.89%	-9.46%
% of Operating Profit
Other Income/Expense, Net	$179.0K	-$51.00K	-$90.00K
YoY Change	316.28%	-112.91%
Pretax Income	-$13.29M	-$12.51M	-$25.24M
YoY Change	-43.46%	-42.19%
Income Tax	-$202.0K	-$1.207M	$40.00K
% Of Pretax Income
Net Earnings	-$13.09M	-$11.30M	-$25.12M
YoY Change	-46.48%	-47.78%
Net Earnings / Revenue	-21.51%	-20.94%	-76.42%
Basic Earnings Per Share
Diluted Earnings Per Share	-$137.1K	-$130.3K	-$292.7K
COMMON SHARES
Basic Shares Outstanding	92.97M shares	87.11M shares	85.75M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$523.0M	$545.6M	$419.0M
YoY Change	92.78%	107.14%
Cash & Equivalents	$147.2M	$174.7M	$140.5M
Short-Term Investments	$375.8M	$371.0M	$278.4M
Other Short-Term Assets	$5.700M	$4.100M	$5.200M
YoY Change	42.5%	36.67%
Inventory	$14.76M	$14.18M	$9.136M
Prepaid Expenses
Receivables	$39.69M	$40.36M	$35.69M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$583.1M	$604.2M	$469.0M
YoY Change	96.26%	112.91%	93.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.76M	$34.81M	$31.00M
YoY Change	34.44%	18.81%	93.33%
Goodwill	$2.928M		$0.00
YoY Change
Intangibles	$8.755M	$8.987M	$0.00
YoY Change
Long-Term Investments	$302.6M	$277.3M	$77.60M
YoY Change	9986.67%	633.6%
Other Assets	$3.073M	$3.159M	$2.046M
YoY Change	58.73%	-73.89%	3.65%
Total Long-Term Assets	$365.3M	$335.7M	$118.4M
YoY Change	668.7%	324.99%	18.41%
TOTAL ASSETS
Total Short-Term Assets	$583.1M	$604.2M	$469.0M
Total Long-Term Assets	$365.3M	$335.7M	$118.4M
Total Assets	$948.3M	$940.0M	$587.4M
YoY Change	175.2%	159.09%	71.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.05M	$15.70M	$10.64M
YoY Change	-7.85%	82.56%	112.93%
Accrued Expenses	$17.24M	$11.09M	$7.178M
YoY Change	130.41%	-31.11%	12.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$67.82M	$57.05M	$46.94M
YoY Change	111.6%	91.44%	139.18%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	-50.0%
Other Long-Term Liabilities	$1.220M	$1.303M	$325.0K
YoY Change	492.23%	-91.37%
Total Long-Term Liabilities	$1.220M	$1.303M	$325.0K
YoY Change	492.23%	-91.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$67.82M	$57.05M	$46.94M
Total Long-Term Liabilities	$1.220M	$1.303M	$325.0K
Total Liabilities	$86.44M	$77.72M	$62.45M
YoY Change	82.12%	-9.74%	81.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$327.6M	-$314.8M	-$280.8M
YoY Change	28.13%		43.46%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$815.4M	$815.5M	$483.2M
YoY Change
Total Liabilities & Shareholders Equity	$948.3M	$940.0M	$587.4M
YoY Change	175.2%	159.09%	71.29%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q4
OPERATING ACTIVITIES
Net Income	-$13.09M	-$11.30M	-$25.12M
YoY Change	-46.48%	-47.78%
Depreciation, Depletion And Amortization	$2.500M	$2.200M	$6.100M
YoY Change	47.06%	69.23%	335.71%
Cash From Operating Activities	$1.350M	-$13.84M	-$26.54M
YoY Change	-106.12%	-18.78%	47.53%
INVESTING ACTIVITIES
Capital Expenditures	-$8.450M	-$3.040M	-$2.930M
YoY Change	42.98%	-58.58%	-1.01%
Acquisitions
YoY Change
Other Investing Activities	-$27.28M	-$317.5M	-$194.8M
YoY Change	-189.83%	-1764.81%	109.71%
Cash From Investing Activities	-$35.73M	-$320.5M	-$197.7M
YoY Change	-246.08%	-2832.57%	106.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.870M	355.1M	250.4M
YoY Change	758.75%	771.77%	500620.0%
NET CHANGE
Cash From Operating Activities	1.350M	-13.84M	-26.54M
Cash From Investing Activities	-35.73M	-320.5M	-197.7M
Cash From Financing Activities	6.870M	355.1M	250.4M
Net Change In Cash	-27.51M	20.70M	26.13M
YoY Change	-957.01%	-41.56%	-122.97%
FREE CASH FLOW
Cash From Operating Activities	$1.350M	-$13.84M	-$26.54M
Capital Expenditures	-$8.450M	-$3.040M	-$2.930M
Free Cash Flow	$9.800M	-$10.80M	-$23.61M
YoY Change	-160.72%	11.34%	57.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	92965751	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Guardant Health, Inc.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q4	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	343000	USD
	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	51000	USD
	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	0	USD
	gh	Variable Interest Entity Fair Value Of Joint Venture Threshold For Share Purchase VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase	0.4
	gh	Variable Interest Entity Threshold Percentageof Fair Valuethatis No Less Than Internal Rateof Return VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn	0.2
	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	151000	USD
CY2019Q2	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	1417000	USD
CY2018Q4	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	7338000	USD
CY2019Q2	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	7136000	USD
CY2018Q2	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	1560000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	4061000	USD
	gh	Noncash Interest Expense Paid NoncashInterestExpensePaid	0	USD
	gh	Numberof Parties With Patent License Agreement NumberofPartiesWithPatentLicenseAgreement	4	party
	gh	Offering Costs Incurredbut Notyet Paid OfferingCostsIncurredbutNotyetPaid	1794000	USD
	gh	Offering Costs Incurredbut Notyet Paid OfferingCostsIncurredbutNotyetPaid	485000	USD
CY2017Q1	gh	Payment In Connection Witha License Agreement PaymentInConnectionWithaLicenseAgreement	9700000	USD
CY2018Q4	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	381776000	USD
CY2019Q2	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	677298000	USD
CY2019Q2	gh	Contractual Obligation Future Minimum Payments Interest Includedin Payments ContractualObligationFutureMinimumPaymentsInterestIncludedinPayments	5509000	USD
CY2019Q2	gh	Contractual Obligation Future Minimum Payments Present Valueof Net Minimum Payments ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments	7136000	USD
CY2018Q2	gh	Costof Development Services CostofDevelopmentServices	453000	USD
	gh	Costof Development Services CostofDevelopmentServices	1661000	USD
CY2019Q2	gh	Costof Development Services CostofDevelopmentServices	2183000	USD
	gh	Costof Development Services CostofDevelopmentServices	4695000	USD
CY2018Q2	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	9506000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	17551000	USD
CY2019Q2	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	14650000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	25673000	USD
CY2018Q4	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	381858000	USD
CY2019Q2	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	676042000	USD
CY2018Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	814000	USD
CY2019Q2	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	1610000	USD
	gh	Increase Decrease In Capital Expenditures Incurred But Not Yet Paid IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid	4986000	USD
	gh	Increase Decrease In Capital Expenditures Incurred But Not Yet Paid IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid	3874000	USD
	gh	Noncash Interest Expense Paid NoncashInterestExpensePaid	7000	USD
CY2019Q2	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	11911000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	19729000	USD
CY2018Q2	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	17822000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	32013000	USD
CY2019Q2	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	42064000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	70901000	USD
CY2018Q2	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.02
	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.02
CY2019Q2	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.03
	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.02
CY2018Q4	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	508847	shares
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	886	shares
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross	55712	shares
CY2018Q1	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	4000	USD
CY2018Q2	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	2000	USD
CY2019Q1	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	56000	USD
CY2019Q2	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	205000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-150000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1276000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10642000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	15700000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35690000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40363000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1470000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1713000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40597000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7081000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11092000	USD
CY2019Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	74000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	243000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	486000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	119000	USD
CY2019Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	80000	USD
CY2018Q2	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	41000	USD
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	105000	USD
CY2019Q2	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	21000	USD
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	51000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1791000	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1783000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	707000	USD
CY2019Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1324000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16634000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18365000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-83000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1344000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	764033000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1128938000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1277000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1180000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3183000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3215000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	723000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1180000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2457000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3215000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6397000	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	239000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	428000	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65857000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65959000	shares
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6550000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7116000	shares
CY2018Q4	us-gaap	Assets Assets	587403000	USD
CY2019Q2	us-gaap	Assets Assets	939989000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	468991000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	604248000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	235000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1260000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	317000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1135000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	97000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111192000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140544000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	174653000	USD
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12067162	shares
CY2019Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9980595	shares
	us-gaap	Costs And Expenses CostsAndExpenses	77424000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	69243000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38596000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34109000	USD
CY2018Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	504000	USD
CY2019Q2	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	346000	USD
CY2019Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	198000	USD
CY2019Q2	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	36000	USD
CY2019Q2	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	108000	USD
CY2019Q2	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	44000	USD
CY2019Q2	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	154000	USD
CY2019Q2	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	54000	USD
CY2018Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	294000	USD
CY2019Q2	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	187000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140544000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	174653000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72596000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	1705000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	129562000	USD
CY2018Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	12986000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35643000	USD
CY2019Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	13687000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10589000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36224000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	USD
CY2019Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1235000	USD
CY2019Q2	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	1421000	USD
CY2019Q2	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	1421000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-21501000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-35643000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10289000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-31224000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16100000	USD
CY2019Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16500000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	13600000	USD
CY2019Q2	us-gaap	Contractual Obligation ContractualObligation	12645000	USD
CY2019Q2	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	5683000	USD
CY2019Q2	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	1705000	USD
CY2019Q2	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	710000	USD
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	42085000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0000001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0000001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85832454	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92806252	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85832454	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92806252	shares
CY2018Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2019Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21501000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1235000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7844000	USD
CY2019Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10912000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16138000	USD
CY2019Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16496000	USD
CY2018Q2	us-gaap	Depreciation Depreciation	1300000	USD
	us-gaap	Depreciation Depreciation	2500000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1496000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.92
CY2019Q2	us-gaap	Depreciation Depreciation	2200000	USD
	us-gaap	Depreciation Depreciation	4300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2964000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5011000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.75
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2939000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-866000	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.03
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M21D
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M2D
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	17500000	USD
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	15300000	USD
CY2018	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y0M0D
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y6M0D
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7800000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7800000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7300000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7313000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8997000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15516000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13439000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26100000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	0	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21636000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-35480000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-12507000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-33832000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1207000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1181000	USD
CY2019Q2	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1200000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	823000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3413000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2224000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-234000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2482000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-3068000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1235000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	760000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	358000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	51000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	701000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-559000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5040000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-255000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1129000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1122000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8987000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	317000	USD
	us-gaap	Interest Expense InterestExpense	648000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	287000	USD
	us-gaap	Interest Expense InterestExpense	580000	USD
	us-gaap	Interest Paid Net InterestPaidNet	51000	USD
	us-gaap	Interest Paid Net InterestPaidNet	580000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	9136000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	14176000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	989000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1974000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3099000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5584000	USD
CY2018Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2200000	USD
CY2019Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1600000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2900000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	62451000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	77715000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	587403000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	939989000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46944000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	57049000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	278417000	USD
CY2019Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	370974000	USD
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	77563000	USD
CY2019Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	277301000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42001000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	357356000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20195000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-305198000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23600000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18139000	USD
CY2018Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2019Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	5000000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21639000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35483000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11600000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37651000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22703000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-41350000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15268000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	61656000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38932000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	96000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2746000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9022000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	8388000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	8144000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7280000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	26076000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1956000	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3245000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2046000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3159000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	159000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	90000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-298000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	138000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-160000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	416000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1011000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1427000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	300000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	5000000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	138000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-160000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	852000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1337000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	206000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1303000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	395000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4544000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	172000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	168000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	326000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9765000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	44070000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	418841000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11360000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5752000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5204000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4082000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	129160000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	249500000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	350432000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	41000000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	75625000	USD
CY2019Q2	us-gaap	Revenues Revenues	53975000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1734000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5530000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1933000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-13844000	USD
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-21639000	USD
	us-gaap	Profit Loss ProfitLoss	-35483000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-21351000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-11300000	USD
	us-gaap	Profit Loss ProfitLoss	-32651000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47637000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	53176000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31003000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34811000	USD
CY2019Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-4700000	USD
CY2019Q2	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-300000	USD
CY2018Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	41800000	USD
CY2019Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	46800000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	399000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	62000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11554000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19809000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19532000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35848000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280799000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-314809000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275892000	USD
CY2018Q2	us-gaap	Revenues Revenues	19382000	USD
	us-gaap	Revenues Revenues	36074000	USD
	us-gaap	Revenues Revenues	90630000	USD
CY2018Q2	us-gaap	Royalty Expense RoyaltyExpense	445000	USD
	us-gaap	Royalty Expense RoyaltyExpense	617000	USD
CY2019Q2	us-gaap	Royalty Expense RoyaltyExpense	1100000	USD
	us-gaap	Royalty Expense RoyaltyExpense	1700000	USD
CY2018Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11575000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22887000	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19439000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	37246000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2457000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6397000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3556507	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3358358	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	288655	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	55712	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.24
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.06
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	296848000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	276781000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	483152000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	51.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	43.35
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	250495000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	458782000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7588405	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5677472	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.58
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.54
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2370282	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.28
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.08
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	70.53
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	194852000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y7M27D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y0M25D
CY2019Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	71.00
CY2019Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	1106	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1677990	shares
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1933000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	349709000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1103000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	424000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	538000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4992000	USD
CY2018Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	172000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	308606000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	468134000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	815474000	USD
CY2018Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.7378
CY2019Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	5200000	USD
CY2019Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	4900000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	48300000	USD
CY2019Q2	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	45100000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	1200000	USD
CY2019Q2	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	984000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12388000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12155000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89036000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87494000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also invests in investment‑grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, estimation of potential credit losses on accounts receivable, the valuation of inventory, the fair value of assets acquired and liabilities assumed for business combinations, goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-19-010189-index-headers.html	Edgar Link	pending
0001628280-19-010189-index.html	Edgar Link	pending
0001628280-19-010189.txt	Edgar Link	pending
0001628280-19-010189-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-06302019x10q.htm	Edgar Link	pending
gh-0630x2019x10qxexhibit311.htm	Edgar Link	pending
gh-0630x2019x10qxexhibit312.htm	Edgar Link	pending
gh-0630x2019x10qxexhibit321.htm	Edgar Link	pending
gh-0630x2019x10qxexhibit322.htm	Edgar Link	pending
gh-20190630.xml	Edgar Link	completed
gh-20190630.xsd	Edgar Link	pending
gh-20190630_cal.xml	Edgar Link	unprocessable
gh-20190630_def.xml	Edgar Link	unprocessable
gh-20190630_lab.xml	Edgar Link	unprocessable
gh-20190630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2019 Q3 Form 10-Q Financial Statement

#000162828019010189 Filed on August 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2019 Q3 Form 10-Q Financial Statement

#000162828019010189 Filed on August 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh